ABSTRACT: Elements consistent with a cell mediated immune response were identified immunohistochemically in amyotrophic lateral sclerosis (ALS) spinal cord and Alzheimer disease (AD) hippocampus. T helper/inducer and cytotoxic/suppressor lymphocytes were detected in affected tissues in both diseases. In addition, abundant reactive microglia were found expressing the major histocompatibility glycoproteins HLA-A,B,C and HLA-DR, as well as receptors for the Fc chain (FcyRl), for complement 3 and 4, and for vitronectin. In AD, the complement proteins Clq, C4d, C3d and C5b-9 were found on dystrophic neurites, neuropile threads and some neurofibrillary tangles. In ALS, the only complement proteins identified were C4d and C3d. The integrin ligands vitronectin and ICAM-1 were also identified in affected tissues in both diseases. RESUME: Reactions du systeme immunitaire dans les maladies neurodegeneratives chroniques. Nous avons identifie par immunohistochimie des elements compatibles avec une reponse immunitaire a mediation cellulaire dans la moelle epiniere de patients atteints de sclerose laterale amyotrophique (SLA) et dans l'hippocampe de patients atteints de la maladie d'Alzheimer (MA). Des lymphocytes T auxiliaires/inducteurs et cytotoxiques/suppresseurs ont ete detected au niveau des tissus atteints dans les deux maladies. De plus, nous avons retrouve une microglie reactive exprimant les glycoproteines majeures d'histocompatibilite, HLA-A,B,C et HLA-DR, ainsi que les recepteurs pour la chaine Fc (FcyRI), pour le complement 3 et 4, et pour la vitronectine. Dans la MA, les proteines du complement Clq, C4d, C3d et C5b-9 ont ete obsersees sur les neurites dystrophiques, les neuropiles et certains amas neurofibrillaires. Dans la SLA, les seules proteines du complement identifiees etaient C4d et C3d. Deux ligands, la vitronectine et ICAM-1, ont egalement ete identifies au niveau des tissus atteints dans les deux maladies.
Great strides have been made in the field of neuroscience during this century. Extensive information has become available concerning the functional neuroanatomy of the brain, the chemistry of the synapse, the electrophysiology of neurons, and the nature of drug-receptor interactions. However, almost no advances have been made in understanding the causes of neuronal death. As a result, there is no effective treatment, nor is there any method of preventing such universally fatal disorders as amyotrophic lateral sclerosis (ALS), Alzheimer disease (AD), Pick's disease, Shy-Drager syndrome, and a host of other chronic degenerative neurological disorders. These diseases have in common the premature death of neurons in selective brain areas, while other brain areas and peripheral organs are left relatively undisturbed.
The role of the immune system has not been systematically explored in these disorders. One reason may be the general belief that the brain is immunologically privileged. The existence of the blood/brain barrier, the absence of conventional lymphatic drainage, the failure of neurons to express MHC antigens, and the usual tolerance of brain to transplanted tissue have all reinforced this concept. Nevertheless, it is well known that the immune system responds to acute infections in the brain in much the same way as in other organs of the body. The same seems to be true for slow viral infections. Thus, the concept of immunological privilege, if it has validity at all, needs to be assessed in terms of the circumstances where it might apply.
In particular, the reactions which characterize chronic brain inflammation need to be carefully evaluated. Multiple sclerosis, and its experimental model, experimental allergic encephalitis, are the most studied chronic inflammatory states. These, however, involve a relapsing attack on a replaceable cell, the oligodendrocyte. Neurons are affected only secondarily. What about circumstances where neurons are the primary target? While there are models of acute neuronal death, especially from excitotoxins, there are not good models of chronic neuronal death apart from the slow virus disorders. Nevertheless, it is progressive and selective neuronal death which characterizes diseases such as AD and ALS. Do they represent a chronic inflammation of the brain? The only available approach is to investigate these diseases directly in terms of the presence of immune system cells and proteins, and to try and draw conclusions about the nature of the mechanisms involved. The reactions that need to be distinguished are those generated by a persistent pathogen, those involving autoimmune attack, and those representing passive phagocytosis of neuronal debris. Such distinctions cannot easily be made, particularly when the various processes occur in combination. To assist in this process, we summarize here recent data from our laboratory on immunohistochemical staining of brain tissue using antibodies to various immune system proteins in two chronic degenerative neurological diseases: AD and ALS. In AD, cognitive functions are severely affected, while motor functions are relatively spared. In ALS, the reverse is true.
Antibodies to the following protein types were used: T-lymphocyte markers for helper/inducer (CD4) and cytotoxic/suppressor (CD8) classes; the leucocyte common antigen marker (LCA, CD45); the class I and class II major histocompatibility complex glycoproteins, HLA-A,B,C and HLA-DR; the complement proteins Clq, C3d, C4d and C5b-9; the integrins LFA-1 (CD 11a), complement receptor 3 (CR3, CD lib), complement receptor 4 (CR4, CD lie), and vitronectin receptor; the integrin ligands intracellular adhesion molecule 1 (ICAM-1) and vitronectin (S protein); and the immunoglobulin receptor FcgRl ( Table-1) .
In chronic inflammatory states, the cell-mediated immune response is generally considered to be generated by T-lymphocytes. The antigens against which the immune response is to be directed are presented to T-lymphocytes by antigen presenting cells. The antigens presented are not full-size proteins; they are short peptides selected by the antigen presenting cell as being foreign and therefore worthy of immune system response. There are two requirements for T cells to recognize the antigen. The first is that it must be presented on a "platter" which is a special p pleated segment of MHC glycoproteins. 1 The second is that the particular peptide matches a T cell receptor for that conformation. 2 Thus, a cell mediated immune response requires the presence of T-lymphocytes and MHC glycoproteins on antigen presenting cells. Table 1 shows that in both AD and ALS, Tlymphocytes of both the helper/inducer and cytotoxic/suppressor classes are present in affected tissue. Moreover, in both diseases abundant reactive microglia are present which express HLA-A, B, and C and HLA-DR. [3] [4] [5] [6] [7] [8] [9] As previously reported, all capillary endothelial cells, whether in normal or affected brain areas, strongly express MHC class 1 antigens.
4 Leucocyte common antigen is expressed moderately strongly by resting microglia, and very strongly by reactive microglia and all leucocytes. 10 Thus, it reveals the presence of leucocytes marginating along capillary walls and infiltrating the tissue matrix in affected areas in both AD and ALS. In addition to identifying resting microglia, it identifies reactive microglia by the intensity of the antigen-antibody reaction and changed morphology of the cells. LCA is one of many phenotypic markers linking microglia with blood monocytes and their tissue derivatives.
Complement proteins associated with the classical, but not the alternative, pathway are also found in A D " 1 2 and ALS 8 tissue. The principal initiator of the classical pathway is an antigen-antibody complex to which CI can bind, but trypsin-like proteins and heparin sulfate-type compounds can also start the cascade. C4 and C3 are cleaved, with the larger fragments chemically binding to tissue near the site of initiation. These fragments degrade, leaving tissue bound C4d and C3d. These two complement proteins are a particularly revealing combination to detect in tissue. They are amplification products and thus are more readily detected than the initiating molecules. They are chemically bound products and not subject to dissociation. 
THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
Finally, the presence of C4, which is not part of the alternative pathway, confirms that the classical pathway has been initiated. The chemically attached fragments opsonize the tissue, although it is not yet certain which parts bind to the P-2 integrin complement receptors. The remaining components C5, C6, C7, C8 and C9, can undergo a series of reactions culminating in the formation of the membrane attack complex, C5b-9. This can insert into lipid bilayers causing cell lysis. It is not intended for most membranes. Its purpose is to attack bacteria and other foreign cells. If host cells are inadvertently attacked, bystander lysis can occur. In AD tissue, antibodies to Clq, C3d and C4d prominently stain amyloid deposits, dystrophic neurites, neuropile threads and some neurofibrillary tangles." Antibodies to C5b-9 stain some dystrophic neurites, neuropile threads and neurofibrillary tangles, but not extracellular deposits." In ALS spinal cord, only staining for C4d and C3d has so far been detected, primarily on oligodendroglial processes. 8 We have described these as complement activated oligodendroglia. 13 The activators of complement reactions in AD and ALS are uncertain. Immunoglobulins have been reported in AD tissue 14 but the interpretation of this has been questioned. 15 Anti-ganglioside antibodies in some ALS sera have been reported, with more than 50% of cases showing such antibodies in some studies; 16 this, however, is not a finding specific for ALS. Whether or not specific antibodies initiate the complement reactions in AD and ALS, immunoglobulin Fc receptors are present in abundance on all microglial cells." The FcyRl receptor levels are sharply increased on reactive microglia in these diseases."
This receptor is highly localized to monocytes, establishing another link between monocytes and microglia.
Microglia constitutively express (3-2 integrins, which are also known as leucocyte adhesion proteins. 17 They too are upregulated when microglia become activated, and therefore can be observed in affected AD and ALS tissue. There are three members for the p-2 family: LFA-1 (CD 11a), and the complement receptors CR3 (CD1 lb) and CR4 (CD1 lc). The ligand for LFA-1 is ICAM-1. ICAM-1 staining of all capillaries is observed in normal tissue since it is produced by endothelial cells. In affected AD and ALS tissue, there is patchy, diffuse staining of the extracellular matrix, suggesting the possibility of chemotactic guidance to some areas of pathology.
Vitronectin, otherwise known as complement S-protein, binds to C5b-9. In the soluble state, this binding inhibits insertion of the membrane attack complex. However, it also binds to the complex when inserted, and in this situation it may act as an opsonizer for the vitronectin receptor. This receptor is an unusual integrin in that the subunit may be associated with more than one B subunit. 18 Vitronectin is normally found in serum, and thus staining for it is found in vessels containing residual plasma. Staining for vitronectin is also found on plaques and tangles in AD tissue 18 and on some membranes in ALS spinal cord. 8 The vitronectin receptor is upregulated on reactive microglia in both AD and ALS. three of these receptors, C4d, C3d and vitronectin, were found attached to damaged neurons, in addition to extracellular debris, in AD. The membrane attack complex was found on neuronal tissue only in AD. T-lymphocytes were found in affected areas in both AD and ALS, as were reactive microglia expressing high levels of MHC glycoproteins. These data are all consistent with the presence of a cell mediated immune response in both diseases, although the reasons for its initiation remain unclear.
